Last reviewed · How we verify
PF-4217329 - Highest Dose — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
PF-4217329 - Highest Dose (PF-4217329 - Highest Dose) — Pfizer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PF-4217329 - Highest Dose TARGET | PF-4217329 - Highest Dose | Pfizer | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PF-4217329 - Highest Dose CI watch — RSS
- PF-4217329 - Highest Dose CI watch — Atom
- PF-4217329 - Highest Dose CI watch — JSON
- PF-4217329 - Highest Dose alone — RSS
Cite this brief
Drug Landscape (2026). PF-4217329 - Highest Dose — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-4217329-highest-dose. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing